When assessing enrichment pathways in the MDM2/MYC amplification group by GSEA within grade III ER+HER2− breast cancer, we identified that grade III ER+HER2− patients with MDM2/MYC amplification were enriched in cell cycle KEGG pathway (Fig. 4J,K, Tables S18 and S19). This evidence concerns the gene MYC and breast cancer.